{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:19:39Z","timestamp":1781662779572,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.virusres.2020.198262","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T03:26:11Z","timestamp":1608089171000},"page":"198262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A retrospective comparison of drugs against COVID-19"],"prefix":"10.1016","volume":"294","author":[{"given":"Jiahong","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.virusres.2020.198262_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5582\/ddt.2020.03008","article-title":"Treatment of SARS-CoV-2: How far have we reached?","volume":"14","author":"Ahsan","year":"2020","journal-title":"Drug Discov. Ther."},{"issue":"5","key":"10.1016\/j.virusres.2020.198262_bib0010","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)","volume":"46","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.virusres.2020.198262_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2020.09.019","article-title":"Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: a retrospective cohort study","author":"Almazrou","year":"2020","journal-title":"J. Saudi Pharm. Soc."},{"issue":"4","key":"10.1016\/j.virusres.2020.198262_bib0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.virusres.2020.198262_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/phar.2467","article-title":"Hydroxychloroquine in hospitalized COVID\u201019 patients: real world experience assessing mortality","author":"Annie","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.virusres.2020.198262_bib0030","article-title":"Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virusres.2020.198262_bib0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antiviral Res."},{"issue":"19","key":"10.1016\/j.virusres.2020.198262_bib0040","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2020.198262_bib0045","article-title":"Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection","author":"Carafoli","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.virusres.2020.198262_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.571156","article-title":"Efficacy and safety of corticosteroid treatment in patients with COVID-19: a systematic review and meta-analysis","volume":"11","author":"Cheng","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.virusres.2020.198262_bib0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/acem.14005","article-title":"A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19","volume":"27","author":"Chowdhury","year":"2020","journal-title":"Acad. Emerg. Med."},{"issue":"7\u20138","key":"10.1016\/j.virusres.2020.198262_bib0060","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1345\/aph.1A363","article-title":"Kaletra (lopinavir\/ritonavir)","volume":"36","author":"Corbett","year":"2002","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.virusres.2020.198262_bib0065","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J. Infect."},{"issue":"1","key":"10.1016\/j.virusres.2020.198262_bib0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13568-020-01028-0","article-title":"The role of environmental factors to transmission of SARS-CoV-2 (COVID-19)","volume":"10","author":"Eslami","year":"2020","journal-title":"AMB Express"},{"issue":"4","key":"10.1016\/j.virusres.2020.198262_bib0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.9035","article-title":"Caution needed on the use of chloroquine and hydroxychloroquine for coronavirus disease 2019","volume":"3","author":"Fihn","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.virusres.2020.198262_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6493","key":"10.1016\/j.virusres.2020.198262_bib0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1126\/science.abb9332","article-title":"Rapid repurposing of drugs for COVID-19","volume":"368","author":"Guy","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virusres.2020.198262_bib0090","first-page":"15","article-title":"Repurposed antiviral drugs for COVID-19\u2013interim WHO SOLIDARITY trial results","author":"Hongchao Pan","year":"2020","journal-title":"medRixv"},{"issue":"5","key":"10.1016\/j.virusres.2020.198262_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1136","article-title":"Detection of IgM and IgG antibodies in patients with coronavirus disease 2019","volume":"9","author":"Hou","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"20","key":"10.1016\/j.virusres.2020.198262_bib0100","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2174\/0929867324666170316115938","article-title":"The pharmacological mechanisms and therapeutic activities of hydroxychloroquine in rheumatic and related diseases","volume":"24","author":"Hu","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.virusres.2020.198262_bib0105","first-page":"143","article-title":"Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19","author":"Kavanagh","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"13","key":"10.1016\/j.virusres.2020.198262_bib0110","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2020.198262_bib0115","article-title":"Efficacy and safety of Lopinavir\/Ritonavir or arbidol in adult patients with Mild\/Moderate COVID-19: an exploratory randomized controlled trial","author":"Li","year":"2020","journal-title":"Med."},{"key":"10.1016\/j.virusres.2020.198262_bib0120","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1002\/ctm2.119","article-title":"Alteration of serum markers in COVID-19 and implications on mortality","author":"Liu","year":"2020","journal-title":"Clin. Transl. Med."},{"issue":"4","key":"10.1016\/j.virusres.2020.198262_bib0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jmv.25678","article-title":"Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle","volume":"92","author":"Lu","year":"2020","journal-title":"J. Med. Virol."},{"issue":"15","key":"10.1016\/j.virusres.2020.198262_bib0130","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.15.2000125","article-title":"Coronavirus disease (COVID-19): a scoping review","volume":"25","author":"Lv","year":"2020","journal-title":"Euro Surveill."},{"issue":"2","key":"10.1016\/j.virusres.2020.198262_bib0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003495-200161020-00011","article-title":"Oseltamivir: a review of its use in influenza","volume":"61","author":"McClellan","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.virusres.2020.198262_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.virusres.2020.198262_bib0145","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","article-title":"The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses","volume":"90","author":"P\u00e9cheur","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2020.198262_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2020.100776","article-title":"Hydroxychloroquine is effective, and consistently so used early, for Covid-19: a systematic review","author":"Prodromos","year":"2020","journal-title":"New Microbes New Infect."},{"key":"10.1016\/j.virusres.2020.198262_bib0155","first-page":"1","article-title":"Lower COVID-19 mortality in Italian forested areas suggests immunoprotection by Mediterranean plants","author":"Roviello","year":"2020","journal-title":"Environ. Chem. Lett."},{"issue":"10223","key":"10.1016\/j.virusres.2020.198262_bib0160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.virusres.2020.198262_bib0165","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.585888","article-title":"Pathophysiology and potential therapeutic candidates for COVID-19: a poorly understood arena","volume":"11","author":"Samaddar","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.virusres.2020.198262_bib0170","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19)","author":"Sanders","year":"2020","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.virusres.2020.198262_bib0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virusres.2020.198262_bib0180","first-page":"1","article-title":"Drug repurposing approach to fight COVID-19","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"issue":"7","key":"10.1016\/j.virusres.2020.198262_bib0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072657","article-title":"A review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virusres.2020.198262_bib0190","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2143","article-title":"Drugs against SARS\u2010CoV\u20102: What do we know about their mode of action?","author":"Valle","year":"2020","journal-title":"Rev. Med. Virol."},{"issue":"11","key":"10.1016\/j.virusres.2020.198262_bib0195","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.virusres.2020.198262_bib0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"15","key":"10.1016\/j.virusres.2020.198262_bib0205","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/cid\/ciaa272","article-title":"Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China","volume":"71","author":"Wang","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virusres.2020.198262_bib0210","article-title":"Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized","author":"Wei Tang","year":"2020","journal-title":"controlled trial. medRixv"},{"key":"10.1016\/j.virusres.2020.198262_bib0215","series-title":"COVID-19 Weekly Epidemiological Update","author":"WHO","year":"2020"},{"key":"10.1016\/j.virusres.2020.198262_bib0220","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention","author":"Wu","year":"2020","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.virusres.2020.198262_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.virusres.2020.198262_bib0230","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40495-020-00216-7","article-title":"An update on current therapeutic drugs treating COVID-19","volume":"6","author":"Wu","year":"2020","journal-title":"Curr. Pharmacol. Rep."},{"issue":"15","key":"10.1016\/j.virusres.2020.198262_bib0235","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virusres.2020.198262_bib0240","article-title":"An exploratory randomized controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI)","author":"Yueping Li","year":"2020","journal-title":"medRixv"},{"key":"10.1016\/j.virusres.2020.198262_bib0245","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Zhaowei Chen","year":"2020","journal-title":"medRixv"},{"issue":"10240","key":"10.1016\/j.virusres.2020.198262_bib0250","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.virusres.2020.198262_bib0255","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170220311692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170220311692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:10:26Z","timestamp":1759155026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170220311692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":51,"alternative-id":["S0168170220311692"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2020.198262","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective comparison of drugs against COVID-19","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2020.198262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"198262"}}